Regulus Therapeutics (NASDAQ:RGLS) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Regulus Therapeutics (NASDAQ:RGLS – Get Rating) in a report issued on Tuesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Several other research analysts also recently weighed in on the company. Canaccord Genuity Group initiated coverage on Regulus Therapeutics in a report on Monday, November 7th. They issued a “buy” rating and a $9.00 price target for the company. Canaccord Genuity Group initiated coverage on Regulus Therapeutics in a report on Tuesday, November 8th. They issued a “buy” rating and a $9.00 price target for the company. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $12.67.

Regulus Therapeutics Price Performance

Shares of Regulus Therapeutics stock opened at $1.45 on Tuesday. Regulus Therapeutics has a 1 year low of $1.08 and a 1 year high of $3.70. The company has a market capitalization of $21.22 million, a P/E ratio of -0.66 and a beta of 1.67. The business has a 50 day moving average price of $1.49 and a 200 day moving average price of $1.64.

Regulus Therapeutics (NASDAQ:RGLS – Get Rating) last issued its quarterly earnings data on Thursday, November 10th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.50). As a group, research analysts expect that Regulus Therapeutics will post -2.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. BlackRock Inc. increased its holdings in shares of Regulus Therapeutics by 108.5% during the 3rd quarter. BlackRock Inc. now owns 45,614 shares of the biopharmaceutical company’s stock worth $78,000 after buying an additional 23,738 shares during the last quarter. Commonwealth Equity Services LLC increased its holdings in shares of Regulus Therapeutics by 52.3% during the 3rd quarter. Commonwealth Equity Services LLC now owns 33,500 shares of the biopharmaceutical company’s stock worth $56,000 after buying an additional 11,500 shares during the last quarter. Dimensional Fund Advisors LP acquired a new stake in shares of Regulus Therapeutics during the 3rd quarter worth $54,000. Renaissance Technologies LLC increased its holdings in shares of Regulus Therapeutics by 498.2% during the 1st quarter. Renaissance Technologies LLC now owns 133,400 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 111,100 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in shares of Regulus Therapeutics by 42.9% during the 1st quarter. Northern Trust Corp now owns 168,172 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 50,518 shares during the last quarter. 55.47% of the stock is currently owned by institutional investors and hedge funds.

About Regulus Therapeutics

(Get Rating)

Regulus Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.